Business Context and Reporting Period
Company: Odyssey Therapeutics, Inc. (ODTX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Odyssey is a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases. Its most advanced programs are OD-001 (RIPK2 inhibitor, Phase 2a for ulcerative colitis) and OD-002 (SLC15A4 inhibitor, IND-enabling studies). The company has no approved products and has never generated revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 | Balance Sheet (June 30, 2026) |
|---|---|---|---|
| Collaboration Revenue | $0 | $0 | N/A |
| Net Loss | $(52,788) | $(91,050) | N/A |
| Operating Loss | $(55,470) | $(95,250) | N/A |
| Research & Development Expenses | $36,226 | $68,547 | N/A |
| General & Administrative Expenses | $10,511 | $17,861 | N/A |
| Cash, Cash Equivalents & Marketable Securities | N/A | N/A | $433,069 |
| Accumulated Deficit | N/A | N/A | $(659,189) |
| Net Cash Used in Operating Activities | N/A | $(75,543) | N/A |
Material Changes vs. Prior Period
- Initial Public Offering (IPO): In May 2026, the company completed its IPO, raising approximately $254.9 million in net proceeds, plus $23.3 million from a concurrent private placement and $10.0 million from an underwriter option exercise. All convertible preferred stock was converted to common stock upon the IPO.
- Revenue Cessation: Collaboration revenue dropped to zero for the three and six months ended June 30, 2026, compared to $0.96 million and $2.88 million in the prior year periods. This is due to the fulfillment of obligations under agreements with Pfizer and Johnson & Johnson, which expired or concluded in 2025.
- Contingent Consideration: A significant non-cash expense of $8.7 million (Q2) and $8.8 million (YTD) was recorded due to changes in the fair value of contingent consideration related to the Rahko acquisition, driven by the completion of the IPO and updated valuation assumptions. This contrasts with income of $0.6 million in the prior year Q2.
- Liquidity Position: Total cash, cash equivalents, and marketable securities increased from $174.9 million at December 31, 2025, to $433.1 million at June 30, 2026, primarily due to IPO proceeds.
Guidance, Outlook, and Risks
- Outlook: Management estimates that existing cash resources ($433.1 million) are sufficient to fund operations into the second half of 2028. The company expects to continue incurring substantial losses as it advances clinical trials for OD-001 and OD-002.
- Key Risks:
- Development Risk: No products are approved; success depends entirely on clinical trial outcomes for OD-001 and OD-002.
- Capital Requirements: Substantial additional capital will be required in the future. Failure to raise funds could force delays or elimination of programs.
- Third-Party Reliance: The company relies on third-party CROs and CMOs for clinical trials and manufacturing. Disruptions (e.g., geopolitical conflicts in Ukraine or China where some vendors are located) could delay development.
- Contingent Liabilities: Potential future payments of up to $30 million each for the IFM and Rahko acquisitions upon achieving specific milestones or market capitalization thresholds.
Investor Verification Checklist
- Cash Runway: Verify the $433.1 million liquidity figure and the specific assumptions used to project funding sufficiency through late 2028.
- OD-001 Trial Status: Confirm enrollment progress and data readout timelines for the Phase 2a monotherapy trial for ulcerative colitis.
- Contingent Consideration Valuation: Review the specific assumptions (probability of milestones, discount rates) used to value the $14.97 million contingent consideration liability.
- Revenue Pipeline: Assess the likelihood of new collaboration agreements to replace the expired Pfizer and J&J revenue streams.
- Geopolitical Exposure: Evaluate the specific risks associated with clinical trial sites and CROs located in Ukraine and China.